登录 | 注册    关注公众号  
微信公众号
搜索
 > 【RENIN】

RENIN信息

英文名称:Renin
中文名称:肾素
靶点别称:REN,Renin,Angiotensinogenase,Angiotensin-Forming Enzyme,Renin Precursor, Renal,HNFJ2,EC:3.4.23.15,EC 3.4.23.15,EC 3.4.23
上市药物数量:3
临床药物数量:5
最高研发阶段:批准上市

RENIN产品列表

产品库
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
REN-H5221
Human
Human RENIN Protein, His Tag
REN-M5222
Mouse
Mouse RENIN Protein, His Tag
ACRO质量管理体系
 
评论(0)
 

RENIN 分子别名

REN,FLJ10761,Renin,angiotensinogenase

RENIN 分子背景

Renin is also known as REN and angiotensinogenase, is a circulating enzyme that participates in the body's renin-angiotensin system (RAS), and plays an essential role in the elevation of arterial blood pressure and increased sodium retention by the kidney. Renin activates the renin-angiotensin system by cleaving angiotensinogen, produced by the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE, the angiotensin-converting enzyme primarily within the capillaries of the lungs. Renin is secreted from kidney cells, which are activated via signaling from the macula densa, which responds to the rate of fluid flow through the distal tubule, by decreases in renal perfusion pressure (through stretch receptors in the vascular wall), and by sympathetic nervous stimulation, mainly through beta-1 receptor activation. Renin can bind to ATP6AP2, which results in a fourfold increase in the conversion of angiotensinogen to angiotensin I over that shown by soluble renin. In addition, renin binding results in phosphorylation of serine and tyrosine residues of ATP6AP2. The level of renin mRNA appears to be modulated by the binding of HADHB, HuR and CP1 to a regulatory region in the 3' UTR. An over-active renin-angiotension system leads to vasoconstriction and retention of sodium and water. These effects lead to hypertension. Therefore, renin inhibitors can be used for the treatment of hypertension.

RENIN 前沿进展

RENIN上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Aliskiren Hemifumarate 半延胡索酸阿利吉仑 SPP-100; SPP-100A; SPP-100B; CGP-60536; CGP-60536B 批准上市 诺华制药 Enviage, Rasilez, Riprazo, Sprimeo, Tekturna, 锐思力 United States 高血压 Noden Pharma Dac 2007-03-05 缺血性心脏病, 心脏衰竭, 二型糖尿病, 免疫球蛋白a肾病, 心肌梗塞, 冠状动脉病变, 高血压, 左心室肥大, 糖尿病黄斑水肿, 心脏和血管疾病, 原发性高血压, 糖尿病肾病, 终末期肾脏病, 糖尿病, 超重 详情
Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide 半延胡索酸阿利吉仑/苯磺酸氨氯地平/氢氯噻嗪 批准上市 诺华制药 Rasitrio, Amturnide United States 高血压 null 2010-12-21 高血压, 原发性高血压 详情
Aliskiren 阿利吉仑 批准上市 Mainland China 原发性高血压 Novartis Pharma Ag 2010-03-26 原发性高血压 详情

RENIN临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
MT-2765 MT-2765 临床三期 Mitsubishi Tanabe Pharma Corp 高血压 详情
SP-20104 (Sarfez Pharmaceuticals) SP-20104 临床二期 1 A Pharma Gmbh 局灶性节段性肾小球硬化症 详情
Imarikiren hydrochloride TAK-272; SCO-272 临床二期 Takeda Pharmaceutical Co Ltd 肾脏疾病, 高血压, 糖尿病肾病, 肝功能衰退 详情

消息提示

请输入您的联系方式,再点击提交!

确定